In the CREDENCE trial, patients receiving canagliflozin had reduced risks of initiating iron therapy and erythropoiesis-stimulating agents compared with patients receiving placebo.
Triferic is an iron maintenance therapy that delivers between 5 to 7mg of iron with every hemodialysis treatment and maintains hemoglobin without increasing ferritin.
Perioperative transfusion of blood products was not associated with worse clinical outcomes or allosensitization in a study of selected kidney transplant recipients.
The new evidence further supports development of the investigational HIF-PHI, which recently also demonstrated noninferiority to darbepoetin in patients with chronic kidney disease not receiving dialysis.